PanOptica Secures $11 Million to Advance Clinical Development of PAN-90806 – a Novel, Topical Anti-VEGF Eye Drop
BERNARDSVILLE, N.J.--(BUSINESS WIRE)--PanOptica announced that it has secured $11 million in a Series B financing. These funds will enable clinical advancement of PAN-90806.